SCHEMBL3260133

SCHEMBL3260133

C=CCC1=NN(CCCCC)C(=O)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.58
GAA P10253 1/20 0.58
MAPT P10636 1/20 0.58
THRB P10828 1/20 0.58
MGLL Q99685 4/20 0.34
FAAH O00519 3/20 0.34
SHMT2 P34897 1/20 0.32
PTGS1 P23219 3/20 0.31
PTGS2 P35354 3/20 0.31
HTT P42858 3/20 0.31
MAPK1 P28482 2/20 0.31
LMNA P02545 2/20 0.31
GALR3 O60755 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP19A1 P11511 4/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
GBA1 P04062 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269226 0.81 ALDH1A1 (0.65) ALDH1A1GAAMAPTTHRBMGLL
SCHEMBL17247571 0.79 GAA (0.61) ALDH1A1GAAMAPTTHRBMGLL
SCHEMBL17247577 0.76 GAA (0.57) ALDH1A1GAAMAPTTHRBMGLL
SCHEMBL2365151 0.74 ALDH1A1 (1.00) ALDH1A1GAAMAPTTHRBMGLL
SCHEMBL9153141 0.72 GAA (0.96) ALDH1A1GAAMAPTTHRBMGLL
SCHEMBL359437 0.71 ALDH1A1 (0.52) ALDH1A1GAAMAPTTHRBMGLL
SCHEMBL17817456 0.71 ALDH1A1 (0.65) ALDH1A1GAAMAPTTHRBMGLL
SCHEMBL15884808 0.71 ALDH1A1 (0.51) ALDH1A1GAAMAPTTHRBSHMT2
SCHEMBL359186 0.71 ALDH1A1 (0.51) ALDH1A1GAAMAPTTHRBMGLL
SCHEMBL360695 0.71 ALDH1A1 (0.51) ALDH1A1GAAMAPTTHRBMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100376568-C Synthesis method of 5-chloro-1-aryl-4- (4, 5-dicyano-1H-imidazole-2-yl) -3-alkyl-1H-pyrazole derivative EVULTIS (CH) 2008-03-26 CN claimed
EP-1618104-B1 METHOD FOR SYNTHESISING 5-CHLORO-1-ARYL-4-(4, 5-DICYANO-1H-IMIDAZOL-2-YL)-3-ALKYL-1H-PYRAZOLE DERIVATIVES EVULTIS (CH) 2007-06-20 EP claimed
CN-1774436-A Synthesis method of 5-chloro-1-aryl-4- (4, 5-dicyano-1H-imidazole-2-yl) -3-alkyl-1H-pyrazole derivative EVULTIS (CH) 2006-05-17 CN claimed
EP-1618104-A1 METHOD FOR SYNTHESISING 5-CHLORO-1-ARYL-4-(4, 5-DICYANO-1H-IMIDAZOL-2-YL)-3-ALKYL-1H-PYRAZOLE DERIVATIVES Evultis (CH) 2006-01-25 EP claimed
WO-2004092159-A1 METHOD FOR SYNTHESISING 5-CHLORO-1-ARYL-4-(4, 5-DICYANO-1H-IMIDAZOL-2-YL)-3-ALKYL-1H-PYRAZOLE DERIVATIVES EVULTIS (CH) 2004-10-28 WO claimed
US-7678923-B2 Method for synthesizing 5-chloro-1-aryl-4-(4,5-dicyano-1h-imidazol-2-yl)-3-alkyl-1h-pyrazole derivatives EVULTIS (CH) 2010-03-16 US disclosed
CN-100376568-C Synthesis method of 5-chloro-1-aryl-4- (4, 5-dicyano-1H-imidazole-2-yl) -3-alkyl-1H-pyrazole derivative EVULTIS (CH) 2008-03-26 CN disclosed
CN-100376568-C Synthesis method of 5-chloro-1-aryl-4- (4, 5-dicyano-1H-imidazole-2-yl) -3-alkyl-1H-pyrazole derivative EVULTIS (CH) 2008-03-26 CN disclosed
US-20070155811-A1 Method for synthesing 5-chloro-1-aryl-4-(4,5-dicyano-1h-imidazol-2-yl)-3-alkyl-1h-pyrazole derivatives EVULTIS (CH) 2007-07-05 US disclosed
EP-1618104-B1 METHOD FOR SYNTHESISING 5-CHLORO-1-ARYL-4-(4, 5-DICYANO-1H-IMIDAZOL-2-YL)-3-ALKYL-1H-PYRAZOLE DERIVATIVES EVULTIS (CH) 2007-06-20 EP disclosed
EP-1618104-B1 METHOD FOR SYNTHESISING 5-CHLORO-1-ARYL-4-(4, 5-DICYANO-1H-IMIDAZOL-2-YL)-3-ALKYL-1H-PYRAZOLE DERIVATIVES EVULTIS (CH) 2007-06-20 EP disclosed
CN-1774436-A Synthesis method of 5-chloro-1-aryl-4- (4, 5-dicyano-1H-imidazole-2-yl) -3-alkyl-1H-pyrazole derivative EVULTIS (CH) 2006-05-17 CN disclosed
CN-1774436-A Synthesis method of 5-chloro-1-aryl-4- (4, 5-dicyano-1H-imidazole-2-yl) -3-alkyl-1H-pyrazole derivative EVULTIS (CH) 2006-05-17 CN disclosed
EP-1618104-A1 METHOD FOR SYNTHESISING 5-CHLORO-1-ARYL-4-(4, 5-DICYANO-1H-IMIDAZOL-2-YL)-3-ALKYL-1H-PYRAZOLE DERIVATIVES Evultis (CH) 2006-01-25 EP disclosed
EP-1618104-A1 METHOD FOR SYNTHESISING 5-CHLORO-1-ARYL-4-(4, 5-DICYANO-1H-IMIDAZOL-2-YL)-3-ALKYL-1H-PYRAZOLE DERIVATIVES Evultis (CH) 2006-01-25 EP disclosed
WO-2004092159-A1 METHOD FOR SYNTHESISING 5-CHLORO-1-ARYL-4-(4, 5-DICYANO-1H-IMIDAZOL-2-YL)-3-ALKYL-1H-PYRAZOLE DERIVATIVES EVULTIS (CH) 2004-10-28 WO disclosed
WO-2004092159-A1 METHOD FOR SYNTHESISING 5-CHLORO-1-ARYL-4-(4, 5-DICYANO-1H-IMIDAZOL-2-YL)-3-ALKYL-1H-PYRAZOLE DERIVATIVES EVULTIS (CH) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155811-A1 Method for synthesing 5-chloro-1-aryl-4-(4,5-dicyano-1h-imidazol-2-yl)-3-alkyl-1h-pyrazole derivatives CYP3A5, CYP4B1, AADAC ALDH1A1 939/4885GAA 3655/4885MAPT 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.